Evidence generation plan for artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway
5 Minimum evidence standards
The evidence considered by NICE primarily focuses on diagnostic accuracy, clinical outcomes and the impact of the technology on the teledermatology pathway for urgent suspected skin cancer referral. The technology demonstrated potential to support triage for cancerous and non-cancerous lesions. Nevertheless, more information is still needed to fully understand the benefits it may provide. More evidence is needed on:
-
diagnostic accuracy, and comparison with existing teledermatology services
-
diagnostic accuracy in people with black or brown skin
-
the impact on the care pathway.
This evidence is essential to future NICE decision making. It may also potentially inform whether AI technologies can be used autonomously to discharge non-cancer cases while sustaining safe diagnostic accuracy rates.
This page was last updated: